D Aletaha1, G Eberl, V P K Nell, K P Machold, J S Smolen. 1. Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria. daniel.aletaha@meduniwien.ac.at
Abstract
OBJECTIVE: To determine if rheumatologists have changed their views on diagnosis and treatment of early rheumatoid arthritis (RA). METHODS: Three consecutive questionnaires were sent out to international rheumatologists in 1997, 2000, and 2003. The following aspects of early RA were covered: definition; patient referral time; diagnostic means; follow up intervals; and treatment strategies. All initial participants who responded to at least one of the follow up surveys were included in the analysis. RESULTS: RA is now defined by a smaller number of affected joints (monarthritis: 9.8% respondents in 1997 v 17.4% in 2003), and shorter symptom duration (<3 months: 65.5% in 1997 v 85.8% in 2003). Early referrals (<6 weeks) increased (8.9% in 1997 v 17.4% in 2003). Serological test for diagnosis was mostly rheumatoid factor (100% in 2003), but anti-CCP was already used by 17.4% in 2003. Follow up of patients with early RA intensified (every 2 weeks: 16.1% in 1997 v 30.4% in 2003; every month: 47.8% in 2003 v 64.3% in 1997). Treatment with disease modifying antirheumatic drugs (DMARDs) mainly comprised methotrexate, sulfasalazine, and antimalarial drugs. Leflunomide was among the two favourite DMARDs of 10.9% in 2003, whereas no biological agent was so. In 2003, 46.7% respondents started treatment with DMARDs if RA was suspected (30.9% in 1997); no one waited for erosions to occur (7.3% in 1997). CONCLUSION: The data obtained in this study suggest that the concept of diagnosing and treating RA early is accepted by a large proportion of the rheumatological community.
OBJECTIVE: To determine if rheumatologists have changed their views on diagnosis and treatment of early rheumatoid arthritis (RA). METHODS: Three consecutive questionnaires were sent out to international rheumatologists in 1997, 2000, and 2003. The following aspects of early RA were covered: definition; patient referral time; diagnostic means; follow up intervals; and treatment strategies. All initial participants who responded to at least one of the follow up surveys were included in the analysis. RESULTS:RA is now defined by a smaller number of affected joints (monarthritis: 9.8% respondents in 1997 v 17.4% in 2003), and shorter symptom duration (<3 months: 65.5% in 1997 v 85.8% in 2003). Early referrals (<6 weeks) increased (8.9% in 1997 v 17.4% in 2003). Serological test for diagnosis was mostly rheumatoid factor (100% in 2003), but anti-CCP was already used by 17.4% in 2003. Follow up of patients with early RA intensified (every 2 weeks: 16.1% in 1997 v 30.4% in 2003; every month: 47.8% in 2003 v 64.3% in 1997). Treatment with disease modifying antirheumatic drugs (DMARDs) mainly comprised methotrexate, sulfasalazine, and antimalarial drugs. Leflunomide was among the two favourite DMARDs of 10.9% in 2003, whereas no biological agent was so. In 2003, 46.7% respondents started treatment with DMARDs if RA was suspected (30.9% in 1997); no one waited for erosions to occur (7.3% in 1997). CONCLUSION: The data obtained in this study suggest that the concept of diagnosing and treating RA early is accepted by a large proportion of the rheumatological community.
Authors: T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman Journal: Lancet Date: 1999-05-08 Impact factor: 79.321
Authors: M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden Journal: Lancet Date: 1997-08-02 Impact factor: 79.321
Authors: E Tsakonas; A A Fitzgerald; M A Fitzcharles; A Cividino; J C Thorne; A M'Seffar; L Joseph; C Bombardier; J M Esdaile Journal: J Rheumatol Date: 2000-03 Impact factor: 4.666
Authors: A van der Heide; J W Jacobs; J W Bijlsma; A H Heurkens; C van Booma-Frankfort; M J van der Veen; H C Haanen; D M Hofman; G A van Albada-Kuipers; E J ter Borg; H L Brus; H J Dinant; A A Kruize; Y Schenk Journal: Ann Intern Med Date: 1996-04-15 Impact factor: 25.391
Authors: Ahmet Ozgul; Evren Yasar; Nuri Arslan; Birol Balaban; M Ali Taskaynatan; Kutay Tezel; Korhan Baklaci; M Ali Ozgüven; T Alp Kalyon Journal: Rheumatol Int Date: 2008-11-27 Impact factor: 2.631
Authors: Paraskevi E Kosta; Paraskevi V Voulgari; Anastasia K Zikou; Alexandros A Drosos; Maria I Argyropoulou Journal: Arthritis Res Ther Date: 2011-06-09 Impact factor: 5.156
Authors: Theresa Kapral; Florian Dernoschnig; Klaus P Machold; Tanja Stamm; Monika Schoels; Josef S Smolen; Daniel Aletaha Journal: Arthritis Res Ther Date: 2007 Impact factor: 5.156
Authors: Josef S Smolen; Daniel Aletaha; Johannes Grisar; Kurt Redlich; Günter Steiner; Oswald Wagner Journal: Arthritis Res Ther Date: 2008-05-29 Impact factor: 5.156